• Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Rights Issue / Företrädesemission 2020
    • The Share
      • Largest Shareholders
      • Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
    • Events and Presentations
  • News
  • Contact
logo
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Rights Issue / Företrädesemission 2020
    • The Share
      • Largest Shareholders
      • Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
    • Events and Presentations
  • News
  • Contact
Home / Investors / Press releases / Press
  • Overview
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Rights Issue / Företrädesemission 2020
  • The Share
    • Share Monitor
    • Largest Shareholders
    • Share Issuances
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact
  • Events and Presentations
Back to all Press releases

Year-End Report 2019

Date: 2020-02-26

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the year-end report of the financial year 2019. 

Summary of events during year-end report 2019

Twelve months (2019-01-01 – 2019-12-31)

  • Net sales amounted to SEK 0 (SEK 0).
  • Result after financial items amounted to  SEK -6 189 903

(SEK -4 189 311).

  • Earnings per share amounted to SEK  -0,81 (SEK -0,76).
  • Solidity amounted to 93,0 % (96,5 %).

Fourth quarter (2019-10-01 – 2019-12-31)

  • Net sales amounted to 0 SEK (0 SEK).
  • Result after financial items amounted to SEK -2 844 273

(SEK -2 131 958).

  • Earnings per share amounted to SEK -0,37 (SEK -0,39)

Earnings per share: Result for the period divided by 7,633,415 shares as of 2019-12-31 

Solidity: Equity divided by total capital.

Amounts in brackets: Corresponding period in the previous year.

"The Company" and "Alzinova" refers to Alzinova AB, reg.no/org.nr. 556861-8168.

For more information, please contact

Kristina Torfgård, VD

tel: +46 708 46 79 75

E-mail: kristina.torfgard@alzinova.com

Certified Adviser

Corpura Fondkommission AB

E-mail: ca@corpura.se

tel: 0768-532822

Home page: www.corpura.se

About Alzinova AB  

Alzinova AB is engaged in pharmaceutical research and development for treatment of Alzheimer’s disease – one of our major health scourges, without efficient treatment options. The Company's patented technology enables the development of novel therapies, that with high precision could target the substances involved in the formation of the disease and render them harmless. Alzinova's focus is to develop a vaccine as a long-acting therapy for treatment and prevention of Alzheimer's disease. The vaccine is under preclinical development, in preparation for human clinical trials. Alzinova was founded by researchers from the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Release Read

  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • News
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin